Clinical trials: Type 2 Diabetes (T2D)
Type 2 Diabetes Mellitus
Vildagliptin Compared to Gliclazide as Dual Therapy With Metformin in Muslim Patients With Type 2 Diabetes Fasting During Ramadan
To evaluate vildagliptin as compared to gliclazide, given in combination with metformin in Muslim patients with type 2 diabetes fasting during Ramadan.
- Trial name
- STEADFAST (NCT01758380)
- Testing
- Vildagliptin, Gliclazide, Metformin
- Where
- 68 sites in Denmark, Egypt and 14 more
- Volunteers
- 557 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus, Type 2
A Pharmacokinetic Study of MK-3102 in Participants With Impaired Hepatic Function (MK-3102-031)
This study will investigate and compare the pharmacokinetics of a single 25-mg dose of MK-3102 in participants with moderate hepatic impairment and matched healthy participants.
- Trial name
- NCT01767688
- Testing
- MK-3102
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
A 6-Week Study To Determine The Safety And Effect Of An Investigational Drug On Adults With Type 2 Diabetes Mellitus Taking Metformin
A Phase 2a study to evaluate the effects of an investigational compound administered at 200 mg, twice daily (BID), for 6 weeks in adult subjects with Type 2 Diabetes Mellitus (T2DM) on metformin background therapy.
- Trial name
- NCT02053103
- Testing
- PF-05175157
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Pfizer
Type 2 Diabetes Mellitus
Glimepiride vs Metformin as Monotherapy in Pediatric Subjects With Type 2 Diabetes Mellitus
To compare the change in glycemic control from baseline to endpoint (last available posttreatment assessment) as measured by HbA1c in pediatric subjects with type 2 diabetes receiving either glimepiride or metformin as…
- Trial name
- NCT00353691
- Testing
- glimepiride, metformin
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks
The primary objective is to demonstrate superior glycaemic control (HbA1c reduction) after 30 weeks of linagliptin/pioglitazone (5/15, 5/30 and 5/45 mg) versus the respective individual monotherapies of pioglitazone (15 mg, 30…
- Trial name
- NCT01183013
- Testing
- Pioglitazone 15 mg, Pioglitazone 45 mg, Pioglitazone 30 mg
- Where
- 132 sites in United States, Estonia and 4 more
- Volunteers
- 936 people
- Sponsor
- Boehringer Ingelheim
Diabetes, Diabetes Mellitus, Type 2
Observational Study to Evaluate the Safety and Efficacy of NovoMix® 70 in Type 2 Diabetes
This study is conducted in Europe. The aim of this observational study is to evaluate the incidence of adverse events while using NovoMix® 70 under normal clinical practice conditions in Austria.
- Trial name
- INTENSIV (NCT00704223)
- Testing
- biphasic insulin aspart
- Where
- Austria
- Volunteers
- 619 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in The Netherlands, as Part of Local Clinical Practice
The purpose of the study is to collect information on how Rybelsus® works in people with type 2 diabetes and to see if Rybelsus® can lower their blood sugar levels.
- Trial name
- PIONEER REAL (NCT04601740)
- Testing
- Oral Semaglutide
- Where
- Netherlands
- Volunteers
- 145 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy
Primary Objective: To compare the efficacy of a new formulation of insulin glargine and Lantus in terms of change of HbA1c from baseline to endpoint (scheduled at Month 6, Week 26) in participants with type 2 diabetes mellitus…
- Trial name
- EDITION III (NCT01676220)
- Testing
- HOE901-U300 (new formulation of insulin glargine), Lantus (insulin glargine)
- Where
- 217 sites in United States, Bulgaria and 14 more
- Volunteers
- 878 people
- Sponsor
- Sanofi
Diabetes, Diabetes Mellitus, Type 2
Observational Study to Evaluate Safety and Efficacy of Insulin Therapy in Type 2 Diabetes Mellitus Subjects Failing on Oral Anti-diabetic Agents
This study is conducted in Asia. The aim of this observational study is to evaluate the incidence of major hypoglycaemic episodes and other adverse events, and to evaluate efficacy while using insulin under normal clinical…
- Trial name
- NCT00715780
- Testing
- soluble human insulin, biphasic human insulin, insulin NPH
- Where
- Indonesia
- Volunteers
- 1,667 people
- Sponsor
- Novo Nordisk A/S
Obesity, Overweight
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
Study ASC30-302 (AURORA-2) is a Phase III, global, multicenter, randomized, double-blind, placebo-controlled study to investigate the long-term efficacy, safety, and tolerability of three maintenance doses of once-daily oral…
- Conditions
- Obesity, Overweight, Chronic Weight Management, Type 2 Diabetes Mellitus
- Trial name
- AURORA-2 (NCT07743450)
- Testing
- ASC30 tablets A1
- Where
- 135 sites in United States, Czechia and 4 more
- Volunteers
- 1,560 people
- Sponsor
- Ascletis Pharma (China) Co., Limited
Diabetes Mellitus, Type 2
Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin
This is a study to understand efficacy and safety of investigational agent (PF-04937319) compared to approved agent (glimepiride) in patients with diabetes on metformin
- Trial name
- NCT01517373
- Testing
- PF-04937319 10 mg, PF-04937319 50 mg, PF-04937319 100 mg
- Where
- 53 sites in United States, Bulgaria and 5 more
- Volunteers
- 304 people
- Sponsor
- Pfizer
Diabetes, Diabetes Mellitus, Type 2
Trial Investigating the Safety of NNC 0113-0987 in Healthy Male Subjects
This trial is conducted in Europe. The aim of this trial is to investigate safety, tolerability and pharmacokinetics (the exposure of the trial drug in the body) of single doses of NNC 0113-0987 in healthy male subjects.
- Conditions
- Diabetes, Diabetes Mellitus, Type 2, Healthy
- Trial name
- NCT01405261
- Testing
- oral NNC 0113-0987, I.v. NNC 0113-0987
- Where
- United Kingdom
- Volunteers
- 101 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Observational Study on Efficacy and Safety of Liraglutide in Subjects With Type 2 Diabetes
This observational study is conducted in Europe. The aim of this non-interventional (observational) study is to evaluate the efficacy of liraglutide (Victoza®) and to assess the conditions of use of Victoza® in daily medical…
- Trial name
- EVIDENCE (NCT01226966)
- Testing
- liraglutide
- Where
- France
- Volunteers
- 3,152 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Forxiga Tablets Specific Clinical Experience Investigation for Elderly
The purpose of the investigation is to confirm the following under the post-marketing actual use of Forxiga Tablets (hereinafter referred to as Forxiga) in elderly patients.
- Trial name
- NCT02200627
- Where
- 46 sites in Japan
- Volunteers
- 1,724 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency
This clinical trial is designed to provide additional information on the safety and tolerability of vildagliptin (50 mg once daily (qd)) when used in patients with type 2 diabetes mellitus (T2DM) and moderate or severe renal…
- Trial name
- NCT00646542
- Testing
- Vildagliptin
- Where
- 12 sites in Argentina, Australia and 10 more
- Volunteers
- 525 people
- Sponsor
- Novartis
Diabetes Mellitus, Type 2
A Study to Determine the Safety, Tolerability, and Effects of GSK2374697 in Healthy Volunteers
This is a single-blinded, randomized, placebo-controlled, staggered-parallel, escalating dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK2374697 in healthy volunteers.
- Trial name
- NCT01545570
- Testing
- GSK2376497, 0.9% sodium chloride
- Where
- United States
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Type 2
A Drug Interaction Study With Albiglutide and Warfarin
This open-label study evaluates the pharmacokinetics of warfarin when coadministered with albiglutide in healthy adult subjects.
- Trial name
- NCT01147731
- Testing
- warfarin plus albiglutide
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Type 1 Diabetes, Diabetes Mellitus, Type 2
RIGHTEST iFree 2 CGM in Pregnant Women With Diabetes Study
This study will evaluate the accuracy and safety of the RIGHTEST iFree 2 Continuous Glucose Monitoring (CGM) System in pregnant women with type 1 diabetes, type 2 diabetes, or gestational diabetes.
- Conditions
- Diabetes Mellitus, Type 1 Diabetes, Diabetes Mellitus, Type 2, Diabetes, Gestational
- Trial name
- NCT07889388
- Testing
- RIGHTEST iFree 2 Continuous Glucose Monitoring System
- Where
- Germany
- Volunteers
- 104 people
- Sponsor
- Bionime Corporation
Diabetes Mellitus, Type 2
GW823093C For The Treatment Of Type 2 Diabetes Mellitus
This study was designed to find dose response and as extension in treatment of GW823093C.
- Trial name
- NCT00370942
- Testing
- GW823093C A, GW823093C B, GW823093C C
- Where
- 5 sites in Japan
- Volunteers
- 159 people
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes Mellitus
Effects of Lixisenatide Compared to Liraglutide on the Postprandial Plasma Glucose in Patients With Type 2 Diabetes
The purpose of the study is to compare the pharmacodynamic effects of lixisenatide (AVE0010), in comparison to liraglutide, as an add-on treatment to metformin, over a period of 4 weeks of treatment.
- Trial name
- NCT01175473
- Testing
- Lixisenatide (AVE0010), Pen auto-injector, Liraglutide
- Where
- 7 sites in Germany
- Volunteers
- 148 people
- Sponsor
- Sanofi
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.